X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration will advance research into in situ CAR-T cell therapies and evaluate their potential to deliver faster, more effective, and cost-efficient treatments for patients.
Lead Product(s): CAR-T Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Alaya.bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 18, 2024
Details:
SLS-001 (galinpepimut-S) is an immunotherapeutic which targets the Wilms Tumor 1 (WT1) protein and which is investigated in Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma.
Lead Product(s): Galinpepimut-S,Nivolumab
Therapeutic Area: Oncology Product Name: SLS-001
Highest Development Status: Phase IProduct Type: Vaccine
Recipient: Sellas Life Sciences Group
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2023
Details:
Galinpepimut-S (GPS) is an immunotherapeutic which targets the Wilms Tumor 1 (WT1) protein which is present and over-expressed in an array of hematological malignancies and solid tumors.
Lead Product(s): Galinpepimut-s
Therapeutic Area: Oncology Product Name: SLS-001
Highest Development Status: Phase IIIProduct Type: Vaccine
Recipient: Sellas Life Sciences Group
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2022
Details:
DANYELZA (naxitamab-gqgk) is indicated, in combination with granulocyte-macrophage colony-stimulating factor for treatment of pediatric patients 1 year of age and older and adult patients.
Lead Product(s): Naxitamab,GM-CSF
Therapeutic Area: Oncology Product Name: Danyelza
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Y-mAbs Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2022
Details:
The GD2-SADA construct was created using our SADA technology, utilizes a pre-targeted payload delivery method where antibody constructs assemble in tetramers and bind to the tumor target.
Lead Product(s): GD2-SADA,177Lu-DOTA
Therapeutic Area: Oncology Product Name: GD2-SADA
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Y-mAbs Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 12, 2022
Details:
In the study, anti-NDC80 TCRm-redirected T cells demonstrated high specificity in recognizing and killing multiple cancer cell lines. Moreover, no toxicities to healthy leukocytes and hematopoietic stem cells were observed.
Lead Product(s): TCR Mimic CAR-T Cell Therapy
Therapeutic Area: Oncology Product Name: NDC80
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Eureka Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
Under the terms of agreement, Memorial Sloan Kettering Cancer Center will use of its next generation signaling technology (“1XX”) in Abintus’ In Vivo CAR-X products.
Lead Product(s): In Vivo CAR-X Products
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Abintus Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 17, 2021
Details:
The safety profile of the GPS-nivolumab combination was similar to that seen with nivolumab alone, with the addition of only low-grade, temporary local reactions at the GPS injection site, consistent with previously performed clinical studies with GPS.
Lead Product(s): Galinpepimut-S,Nivolumab,Sargramostim
Therapeutic Area: Oncology Product Name: SLS-001
Highest Development Status: Phase IProduct Type: Vaccine
Recipient: Sellas Life Sciences Group
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2021
Details:
The EHA abstract, submitted by Simona Raso, reports that 2 out of 3 Thalassemia patients treated with EGT’s autologous CD34+ cells have sustained dramatic reduction in blood transfusions after 8 and 5 years, respectively.
Lead Product(s): Autologous CD34+ cells,TNS9.3.55
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Recipient: Errant Gene Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2021
Details:
In-licensing these anti-CD371 scFvs further expands Caribou’s pipeline of allogeneic cell therapies for hematological malignancies. CB-010, Caribou’s lead allogeneic CAR-T program, targets CD19 and has been cleared by the FDA for clinical evaluation.
Lead Product(s): Anti-CD371 scFvs based cell therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Caribou Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 18, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
